Compare OPRA & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRA | IRON |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 3.4B |
| IPO Year | 2018 | N/A |
| Metric | OPRA | IRON |
|---|---|---|
| Price | $14.24 | $92.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $23.83 | ★ $108.83 |
| AVG Volume (30 Days) | ★ 652.8K | 553.0K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $583,449,000.00 | N/A |
| Revenue This Year | $27.78 | N/A |
| Revenue Next Year | $14.95 | N/A |
| P/E Ratio | $16.21 | ★ N/A |
| Revenue Growth | ★ 30.29 | N/A |
| 52 Week Low | $12.62 | $30.82 |
| 52 Week High | $22.50 | $99.50 |
| Indicator | OPRA | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 55.66 |
| Support Level | $13.61 | $90.40 |
| Resistance Level | $13.98 | $99.50 |
| Average True Range (ATR) | 0.44 | 3.76 |
| MACD | 0.22 | -0.51 |
| Stochastic Oscillator | 73.98 | 38.72 |
Opera Ltd is a world-wide internet brand with a large, engaged, and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its browser's features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. Geographically, the company generates maximum revenue from the United States, followed by Singapore, Nigeria, Russia, and other locations.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.